1.	Phase III Randomized Study of Zoledronate, Vitamin D, and Calcium With or Without Strontium Chloride Sr 89 or Samarium Sm 153 Lexidronam Pentasodium in Preventing or Delaying Skeletal-Related Events in Patients With Bone Metastases Secondary to Prostate, Lung, or Breast Cancer Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0517, RTOG 0517, NCT00365105
2.	Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 424Sm32, NCT00121095
3.	Effect of Samarium on the Relief of Pain Due to Vertebral Metastases Phase: Phase II, Phase I Type: Supportive care Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: NYM-354, NCT00374751
4.	Phase II Randomized Pilot Study of Samarium Sm 153 Lexidronam Pentasodium With Versus Without Recombinant Fowlpox-TRICOM Vaccine and Recombinant Vaccinia-TRICOM Vaccine in Patients With Androgen-Insensitive, Prostate Cancer Metastatic to the Bone Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-07-C-0106, 07-C-0106, 7678, NCT00450619
5.	Phase II Study of Samarium Sm 153 Lexidronam Pentasodium Followed by Intensity-Modulated Radiation Therapy or Three-Dimensional Conformal Radiation Therapy in Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0622, RTOG 0622, NCT00551525
6.	Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 02C.172, NCT00328614